All In Biotech

Drug Trial Radar · NCT05003713

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT125236 in Healthy Subjects, With an Optional Pharmacological Effects Cohort

Last checked: Nov 19, 2026Latest source record: Mar 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Aug 3, 2021

Primary completion

Feb 3, 2023

Study completion Feb 3, 2023

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 3-part, first-in-human study of single ascending doses (SAD; Part 1) and multiple ascending doses (MAD; Part 2) of CORT125236 in healthy participants; Part 3 is optional, to investigate whether CORT125236 ameliorates the effects of prednisone on various pharmacodynamic (PD) endpoints. The 3 parts may not be conducted entirely sequentially provided that this is justified by the pharmacokinetic (PK) and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from at least 3 SAD levels to allow MAD administration to proceed. The decision on whether to start Part 3 can be made at any point after completion of 3 SAD levels, and will be based on achieving sufficiently high plasma CORT125236 exposure in Part 1 of the study.

Conditions

  • Healthy

Interventions

  • CORT125236Drug

    CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

  • Placebo matching CORT125236Drug

    Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

  • PrednisoneDrug

    Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Adverse EventsTime frame: Part 1 SAD Cohorts: up to Day 12; Part 2 MAD Cohorts: up to Day 25; Part 3 Cohort: up to Day 19

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 01

    Ruddington, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.